Granulation response and partial wound closure predict healingin clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor

Diabetes Care

Volumn 36, Issue 2, 2013, Pages 210-215

  Valenzuela Silva, Carmen M ^a   Tuero Iglesias, Angela D ^a   Garcia Iglesias, Elizeth ^a   Gonzalez Diaz, Odalys ^a   Del Rio Martin, Amaurys ^a   Alos, Isis Belkis Yera ^a   FERNANDEZ MONTEQUiN, Jose I ^b   LóPEZ SAURA, Pedro A ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b National Institute for Angiology and Vascular Surgery   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORRELATION ANALYSIS; DEBRIDEMENT; DIABETIC FOOT; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GRANULATION TISSUE; HUMAN; LOG HEALING RATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PERCENT AREA CHANGE; PERCENT OF GRANULATION TISSUE; POSTMARKETING SURVEILLANCE; PREDICTIVE VALUE; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATIO OF LOG AREAS; RECEIVER OPERATING CHARACTERISTIC; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION STUDY; WOUND CLOSURE; WOUND HEALING;

AGED; DIABETIC FOOT; DOUBLE-BLIND METHOD; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; WOUND HEALING;

EID: 84873826027     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1323     Document Type: Article

References (27)

1. Fleming TR. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 2005;24:67-78
2. Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2003;26:1696-1700
3. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003;26:1879-1882
4. Snyder RJ, Cardinal M, Dauphinée DM, Stavosky J. A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks. Ostomy Wound Manage 2010;56:44-50
5. Lavery LA, Barnes SA, Keith MS, Seaman JW, Armstrong DG. Prediction of healing for postoperative diabetic foot wounds based on early wound area progression. Diabetes Care 2008;31:26-29
6. Frykberg RG, Zgonis T, Armstrong DG, et al.; American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006;45(Suppl.):S1-S66
7. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998;21:855-859
8. Armstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Tech 2011;5: 1591-1595
9. Armstrong DG, Boulton AJM, Andros G, et al. Defining success in clinical trials of diabetic foot wounds: the Los Angeles DFCon consensus. Int Wound J 2009;6: 211-213
10. Leung PC, Wong MW, Wong WC. Limb salvage in extensive diabetic foot ulceration: an extended study using a herbal supplement. Hong Kong Med J 2008;14:29-33
11. Sepúlveda G, Espfndola M, Maureira M, et al. Negative-pressure wound therapy versus standard wound dressing in the treatment of diabetic foot amputation. A randomised controlled trial. Cir Esp 2009; 86:171-177 [in Spanish]
12. EudraCT Register. A feasibility study to evaluate the effect of Vivostat platelet rich fibrin (PRF) in the treatment of diabetic foot ulcers [Internet]. Available from https://www.clinicaltrialsregister.eu/ctr-search/trial/2009- 011755-47/DE. Accessed 25 March 2012
13. Fernandez-MontequnJI, Infante-Cristia E, Valenzuela-Silva C, et al.; Cuban Citoprot-P Study Group. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007;4:333-343
14. Armstrong DG, Lavery LA; Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005;366:1704-1710
15. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008;31:631-636
16. Fernandez-Montequfn JI, Valenzuela-Silva CM, Gonzalez-Diaz O, et al.; Cuban Diabetic Foot Study Group. Intralesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers. Multicenter, randomized, placebo-controlled, double blind study. Int Wound J 2009;6:432-443
17. Heberprot P. Product information. Available from http://heberprot-p.cigb. edu.cu/. Accessed 26 June 2012
18. Sugama J, Matsui Y, Sanada H, Konya C, Okuwa M, Kitagawa A. A study of the efficiency and convenience of an advanced portable Wound Measurement System (VISITRAK). J Clin Nurs 2007;16:1265-1269
19. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Missing Data in Confirmatory Clinical Trials. London, European Medicines Agency, 2009 (CPMP/EWP/1776/99 rev. 1 corr. p. 1-13)
20. Burgueño MJ, Garcia-Bastos JL, Gonzalez-Buitrago JM. ROC curves in the evaluation of diagnostic tests. Med Clin (Barc) 1995; 104:661-670 [in Spanish]
21. MacKinnon DP, Dwyer JH. Estimating mediated effects in prevention studies. Eval Rev 1993;17:144-158
22. MacKinnon DP, Lockwood CM, Brown CH, Wang W, Hoffman JM. The intermediate endpoint effect in logistic and prob it regression. Clin Trials 2 007 ;4:49 9-513
23. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-870
24. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440
25. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-1379
26. Bouwmeester W, Zuithoff NPA, Mallett S, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med 2012;9:1-12
27. Sheehan P. Early change in wound area as a predictor of healing in diabetic foot ulcers: knowing "when to say when". Plast Reconstr Surg 2006;117(Suppl.):245S-247S